# Veniti

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/veniti

- Industry: Medical Devices & Equipment
- Headquarters: Fremont, US
- Website: www.veniti.com
- Total disclosed funding: $48M
- Latest round: Series C (Mar 10, 2015)
- Investors on record: 8

## About

Veniti, Inc. focuses on developing advanced medical devices that enhance patient outcomes through improved data analytics and connectivity, primarily serving the healthcare sector.Founded in 2009 and headquartered in Fremont, US, Veniti, Inc. specializes in creating innovative medical devices. The company underwent a strategic acquisition by Boston Scientific in August 2018 for USD 108 mn, with an additional contingent payment of USD 52 mn pending FDA approval. The company has participated in 8 deals to date, with the most recent deal occurring in 2018.Veniti.com specializes in providing innovative solutions aimed at addressing critical challenges in the healthcare sector. The company's core offerings include advanced medical devices designed to improve patient outcomes through enhanced data analytics and connectivity. These products facilitate seamless integration into existing healthcare systems, allowing healthcare providers to monitor patient metrics in real-time, thereby optimizing treatment protocols. Targeting healthcare institutions and professionals, Veniti.com aims to serve a diverse client base that encompasses hospitals, outpatient clinics, and telehealth providers across North America and Europe. By focusing on improving patient care and operational efficiency, Veniti.com is positioned to meet the growing demands of the healthcare market globally.The revenue model for Veniti.com primarily revolves around direct sales to healthcare providers and institutions, supplemented by strategic partnerships in the healthcare ecosystem. Transactions are structured on a B2B basis, with clients entering into contracts that include provisions for ongoing service and support. The company offers tiered pricing plans for its flagship medical device, which may include options for one-time purchases or subscription services for software updates and data management. This transactional framework allows institutions to tailor their investment according to specific needs, ensuring that clients receive comprehensive support throughout the lifecycle of the product. As a result, Veniti.com is able to create a sustainable revenue stream while facilitating long-term relationships with healthcare entities.In August 2018, Boston Scientific acquired Veniti, Inc. for USD 108 mn in cash, with an additional USD 52 mn contingent on FDA approval. Following this acquisition, Veniti plans to leverage Boston Scientific's extensive resources to expedite the development and launch of new medical devices aimed at enhancing patient care. The company is looking to expand its market presence in Europe and Asia by 2025, focusing on regions with increasing demands for innovative healthcare solutions. The recent funding will be utilized to support these product development initiatives and market expansion efforts.

## Funding rounds

- Series C, Mar 10, 2015, $10M — Baird Capital Partners, Tekla Capital Management, Volcano Capital, Life Sciences Capital
- Series B, May 28, 2013, $9.7M — BPEA Private Equity, Vectis Capital
- Series A, Mar 7, 2011, $14M — Baird Capital Partners, Prolog Ventures, Tekla Capital Management
- Series A, Feb 28, 2011, $15M — Baird Capital Partners, Prolog Ventures, Tekla Capital Management, St. Louis Arch Angels

## Investors

- Baird Capital Partners (https://capitalatlas.ai/funds/baird-capital-partners) — Series A, Series C
- Prolog Ventures (https://capitalatlas.ai/funds/prolog-ventures) — Series A
- Tekla Capital Management (https://capitalatlas.ai/funds/tekla-capital-management) — Series A, Series C
- St. Louis Arch Angels — Series A
- BPEA Private Equity (https://capitalatlas.ai/funds/bpea-private-equity) — Series B
- Vectis Capital (https://capitalatlas.ai/funds/vectis-capital) — Series B
- Volcano Capital (https://capitalatlas.ai/funds/volcano-capital) — Series C
- Life Sciences Capital (https://capitalatlas.ai/funds/life-sciences-capital) — Series C